Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients

NCT05960162 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT05960162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05960162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients
Lead sponsor
Assiut University
Phase
Observational
Overall status
Unknown status
Start date
July 17, 2023
Completion date
July 17, 2024
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ibd